News
Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...
The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced ...
The anti-obesity medication tirzepatide, marketed as Mounjaro for diabetes and Zepbound for obesity, reduced obesity-associated breast ...
The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...
U.S. telehealth upstart Hims & Hers Health, Inc. is planning to enter the Canadian market with an eye to selling generic ...
Both Mounjaro and anti-obesity medication, Ozempic, are typically covered by insurance for people who have diabetes. Rosie O'Donnell gets political: Leaving US for second Trump presidency was ...
Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...
Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results